J&J to pay Emergent $135 million as part of COVID-19 vaccine manufacturing deal [MarketWatch]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: MarketWatch
Shares of Johnson & Johnson were up 0.4% in premarket trading on Friday after the company announced a manufacturing deal with Emergent BioSolutions Inc. for its COVID-19 vaccine candidate. Emergent's stock gained 7.4% before the market opened. J&J has said it plans to launch Phase 1 clinical studies of its vaccine in September, and this deal is part of efforts to ramp up manufacturing capacity. J&J will pay Emergent $135 million, per the agreement, according to Emergent. "We believe that J&J has selected Emergent to be its U.S. based manufacturer of the vaccine," Chardon analysts wrote in a note on Friday. Year-to-date, J&J's stock has gained 6.6%, shares of Emergent are up 23.4%, and the S&P 500 is down 13.4%.
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBCPR Newswire
- Johnson & Johnson (NYSE:JNJ) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson (JNJ): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 10/14/25 - Beat
JNJ
Sec Filings
- 12/1/25 - Form 4
- 11/13/25 - Form 13F-HR
- 10/22/25 - Form 10-Q
- JNJ's page on the SEC website